Table 1.
Baseline characteristics of 281 264 study participants aged 18-65 years who received the Oxford-AstraZeneca vaccine against covid-19 (ChAdOx1) in Denmark and Norway
| Characteristics | Denmark (n=148 792) | Norway (n=132 472) |
|---|---|---|
| Women | 119 119 (80.1) | 102 848 (77.6) |
| Median (interquartile range) age (years): | 45 (33-55) | 44 (32-55) |
| 18-24 | 13 731 (9.2) | 13 092 (9.9) |
| 25-29 | 13 784 (9.3) | 12 704 (9.6) |
| 30-34 | 12 774 (8.6) | 13 002 (9.8) |
| 35-39 | 13 968 (9.4) | 13 199 (10.0) |
| 40-44 | 17 134 (11.5) | 14 365 (10.8) |
| 45-49 | 19 827 (13.3) | 15 582 (11.8) |
| 50-54 | 19 629 (13.2) | 15 916 (12.0) |
| 55-59 | 21 027 (14.1) | 17 630 (13.3) |
| 60-65 | 16 918 (11.4) | 16 982 (12.8) |
| Month vaccinated: | ||
| February 2021 | 84 359 (56.7) | 53 678 (40.5) |
| March 2021 | 64 433 (43.3) | 78 794 (59.5) |